Sensitivity to TOP2 targeting chemotherapeutics is regulated by Oct1 and FILIP1L

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Lu, Huarui ^a   Hallstrom, Timothy C ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ATM PROTEIN; ATR PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; MERBARONE; MITOXANTRONE; OCTAMER TRANSCRIPTION FACTOR 1; RAZOXANE; SBCC PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; FILAMIN A INTERACTING PROTEIN 1LIKE GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE INDUCTION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN LOCALIZATION; TRANSCRIPTION REGULATION; ULTRAVIOLET IRRADIATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; OCTAMER TRANSCRIPTION FACTOR-1; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA INTERFERENCE; TOPOISOMERASE II INHIBITORS;

EID: 84865044887     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042921     Document Type: Article

References (36)

1. Gros P, Ben Neriah Y, Croop JM, Housman DE, (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323:: 728--731.
2. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, et al. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:: 1650--1654.
3. Gottesman MM, Pastan I, (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:: 385--427.
4. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:: 786--792.
5. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:: e73.
6. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:: 117--125.
7. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:: 395--402.
8. Lowe SW, Ruley HE, Jacks T, Housman DE, (1993) p 53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:: 957--967.
9. Pommier Y, Leo E, Zhang H, Marchand C, (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17:: 421--433.
10. Mao Y, Yu C, Hsieh TS, Nitiss JL, Liu AA, et al. (1999) Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Biochemistry 38:: 10793--10800.
11. Hannon GJ, (2002) RNA interference. Nature 418:: 244--251.
12. Silva JM, Li MZ, Chang K, Ge W, Golding MC, et al. (2005) Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 37:: 1281--1288.
13. Burgess D, Doles J, Zender L, Xue W, Ma B, et al. (2008) Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 105:: 9053--9058.
14. Shiloh Y, (2001) ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 11:: 71--77.
15. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, et al. (1998) Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26:: 362--367.
16. Verrijzer CP, Alkema MJ, van Weperen WW, Van Leeuwen HC, Strating MJ, et al. (1992) The DNA binding specificity of the bipartite POU domain and its subdomains. EMBO J 11:: 4993--5003.
17. Tantin D, Schild-Poulter C, Wang V, Haché R, PA S, (2005) The octamer binding transcription factor Oct-1 is a stress sensor. Cancer Res 65:: 10750--10758.
18. Kang J, Gemberling M, Nakamura M, Whitby FG, Handa H, et al. (2009) A general mechanism for transcription regulation by Oct1 and Oct4 in response to genotoxic and oxidative stress. Genes Dev 23:: 208--222.
19. Martin SA, Lord CJ, Ashworth A, (2010) Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res 16:: 5107--5113.
20. Tissier A, Janel-Bintz R, Coulon S, Klaile E, Kannouche P, et al. (2010) Crosstalk between replicative and translesional DNA polymerases: PDIP38 interacts directly with Poleta. DNA Repair 9:: 922--928.
21. Wojtasz L, Daniel K, Roig I, Bolcun-Filas E, Xu H, et al. (2009) Mouse HORMAD1 and HORMAD2, two conserved meiotic chromosomal proteins, are depleted from synapsed chromosome axes with the help of TRIP13 AAA-ATPase. PLoS Genet 5:: e1000702.
22. Tandle AT, Mazzanti C, Alexander HR, Roberts DD, Libutti SK, (2005) Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. Cytokine 30:: 347--358.
23. Kwon M, Hanna E, Lorang D, He M, Quick JS, et al. (2008) Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy. Cancer Res 68:: 7332--7341.
24. Bronner C, Achour M, Arima Y, Chataigneau T, Saya H, et al. (2007) The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future? Pharmacol Ther 115:: 419--434.
25. Jin J, Arias EE, Chen J, Harper JW, Walter JC, (2006) A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell 23:: 709--721.
26. Marchese A, Sawzdargo M, Nguyen T, Cheng R, Heng HH, et al. (1999) Discovery of three novel orphan G-protein-coupled receptors. Genomics 56:: 12--21.
27. Duncan MB, Chen J, Krise JP, Liu J, (2004) The biosynthesis of anticoagulant heparan sulfate by the heparan sulfate 3-O-sulfotransferase isoform 5. Biochim Biophys Acta 167:: 34--43.
28. Mok SC, Wong KK, Chan RK, Lau CC, Tsao SW, et al. (1994) Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 52:: 247--252.
29. Schwarze SR, DePrimo SE, Grabert LM, Fu VX, Brooks JD, et al. (2002) Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem 277:: 14877--14883.
30. Burton ER, Gaffar A, Lee SJ, Adeshuko F, Whitney KD, et al. (2011) Downregulation of Filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer. Mol Cancer Res 9:: 1126--1138.
31. Mazzanti CM, Tandle A, Lorang D, Costouros N, Roberts D, et al. (2004) Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells. Genome Res 14:: 1585--1593.
32. Liu F, Tan G, Li J, Dong X, Krissansen GW, et al. (2007) Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice. Cancer Sci 98:: 1381--1387.
33. Nagano T, Yoneda T, Hatanaka Y, Kubota C, Murakami F, et al. (2002) Filamin A-interacting protein (FILIP) regulates cortical cell migration out of the ventricular zone. Nat Cell Biol 4:: 495--501.
34. Nagano T, Morikubo S, Sato M, (2004) Filamin A and FILIP (Filamin A-Interacting Protein) regulate cell polarity and motility in neocortical subventricular and intermediate zones during radial migration. J Neurosci 24:: 9648--9657.
35. Morita S, Kojima T, Kitamura T, (2000) Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 7:: 1063--1066.
36. Nelson JD, Denisenko O, Bomsztyk K, (2006) Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc 1:: 179--185.